

Good Health and Well-being SDG 3			
2009 h1n1	anti-pd-1f	cancer cell invasion	ckd progression
2009 pandemic	antiretroviral (arv)	cancer cell migration and invasion	ckd stages
22n1	antiretroviral medication	cancer cell survival	classical hodgkin lymphoma
5-year disease-free survival	antiretroviral regimen	cancer cell viability	clear cell rcc
a(h1n1)	antiretroviral treatment (art)	cancer cost	clear cell renal cell carcinoma (ccrcc)
a549 lung cancer	anti-tuberculosis treatment	cancer detection rate	clinical benefit rate
a549 lung cancer cell	apoptosis of cancer cells	cancer development and progression	clinically localized prostate cancer
a549 lung cancer cells	art adherence	cancer diagnoses	clinically significant prostate cancer
abirateron	art initiation	cancer disparities	clinicopathologic factor
abiraterone	artemisinin-based combination	cancer drug delivery	clinicopathologic factors
active surveillance (as)	ascvd	cancer gene expression	clinicopathologic parameter
acute ischemic stroke	asthma care	cancer gene therapy	clinicopathologic parameters
acute ischemic stroke (ais)	asthma children	cancer history	clinicopathologic variable
acute ischemic stroke patients	asthma control questionnaire	cancer inflammation	clinicopathologic variables
acute myeloid leukemia patient	asthma control test	cancer information	co-infected patients
acute stroke treatment	asthma diagnosis	cancer intervention	colorectal cancer (cro) screening
adherence to antiretroviral therapy	asthma exacerbations	cancer mechanism	colorectal cancer cell line
adjuvant chemoradiation	asthma guideline	cancer mouse model	colorectal cancer cell lines
adolescents with type 1 diabetes	asthma guidelines	cancer outcomes	colorectal cancer liver metastases
adult cancer survivors	asthma medication	cancer pain relief	colorectal cancer risk
adult congenital heart	asthma model	cancer pathogenesis	colorectal cancer surgery
adult congenital heart disease	asthma outcome	cancer quality of life	colorectal carcinoma (cro)
adults with cancer	asthma outcomes	cancer registry data	combination antiretroviral therapy
adults with diabetes	asthma phenotype	cancer resection	combination antiretroviral therapy (cart)
adults with type 2 diabetes	asthma prevalence	cancer resistance	common toxicity criteria
advanced chronic kidney disease	asthma quality of life	cancer specific survival	community-acquired pneumonia (cap)
advanced esophageal cancer	asthma risk	cancer stem cell (csc)	complicated malaria
advanced hcc	atezolizumab	cancer stem cell marker	concurrent chemoradiation
advanced hepatocellular carcinoma	atherosclerosis cardiovascular disease	cancer stem-like	concurrent chemoradiotherapy (ccrt)
advanced hepatocellular carcinoma (hcc)	baseline c04	cancer stem-like cell	controlled asthma
advanced melanoma	baseline hba1c	cancer stem-like cells	coronary artery calcium (cac)
advanced non-small cell lung cancer (nsccl)	b-cell lymphoma 2	cancer stemness	crc cell lines
advanced non-small-cell lung cancer	b-cell lymphoma 2 (bcl-2)	cancer strategy	crc risk
advanced non-small-cell lung cancer (nsccl)	b-cell lymphoma-2	cancer survivorship	crc screening
advanced pancreatic cancer	b-cell non-hodgkin lymphoma	cancer susceptibility gene	crizotinib
advanced rectal cancer	bcr-ab1	cancer symptom	cryptogenic stroke
advanced/metastatic	biochemical failure	cancer targeted	csc marker
afatinib	biochemical recurrence (bcr)	cancer targeted therapy	cteph
aggressive prostate cancer	bladder cancer (bc)	cancer theranostic	curative-intent
aicc stage	bovine respiratory disease	cancer therapeutics	current asthma
alcohol use disorder (aud)	braf inhibitor	cancer thyroid	cvd event
alcohol use disorders identification test	braf mutations	cancer xenograft model	cvd events
alcohol use disorders identification test (audit)	braf v600e mutation	cancer-associated fibroblasts (cafs)	cvd mortality
alcohol-dependent patients	brafv600	cancer-related fatigue	definitive chemoradiotherapy
alk inhibitor	brafv600e	cancer-related gene	dengue virus (denv)
alk-positive	brca mutation	cancer-related genes	denv infection
allergy, asthma	brca mutations	cancer-specific mortality	denv-2
american joint committee on cancer (ajcc)	brca1 and brca2 mutation	cancer-specific survival (css)	detectable viral load
aml cell lines	brca1 brca2	cannabis use disorder	diabetes diagnosis
anaplastic lymphoma kinase (alk)	brca1 mutation	carboplatin and paclitaxel	diabetes medication
atherosclerotic cardiovascular disease (ascvd)	brca1 or brca2	carcinoma hepatocellular	diabetes medications
autoimmune hepatitis (aih)	brca1/2 mutation	carcinoma hepatocellular	diabetes mellitus type 1
avian influenza virus (aiv)	brca2 gene	cardioembolic stroke	diabetes mellitus, type 2
avian influenza viruses	brca2 mutation	cardiovascular and cerebrovascular disease	diabetes model
axillary lymph node dissection (alnd)	brca2 mutations	cardiovascular and cerebrovascular diseases	diabetes prevention
b16f10 melanoma	breast and prostate cancer	cardiovascular disease (cvd) risk	diabetes prevention program
barcelona clinic liver cancer	breast cancer cell proliferation	cardiovascular disease (cvd) risk factors	diabetes self-care
basal-like	breast cancer gene	cardiovascular disease prevention	diabetes self-management
anaplastic thyroid cancer	breast cancer mcf-7	castration resistant	diabetes status
and end results database	breast cancer mcf-7 cell	castration-resistant prostate cancer (crpc)	diabetes technology
and type 1 diabetes	breast cancer mcf-7 cells	cause-specific survival	diabetes-related complication
androgen deprivation therapy (adt)	breast cancer model	cervical cancer (cc)	diabetes-related complications
androgen-deprivation	breast cancer recurrence	cervical cancer cell line	diabetic kidney disease (dkd)
androgen-deprivation therapy	breast cancer resistance	cervical cancer prevention	differentiated thyroid cancer (dtc)
androgen-independent prostate cancer	breast cancer resistance protein	chb patients	diffuse large b cell
antenatal care (anc)	breast cancer resistance protein (bcrp)	checkpoint inhibition	diffuse large b cell lymphoma
anthracycline-based	breast cancer stem cell	chemical failure	diffuse large b cell lymphoma (dlbcl)
anthracycline-based chemotherapy	breast cancer stem cells	chemoradiation therapy	diffuse large b-cell lymphomas
anti-cancer activities	breast cancer subtype	chemoradiotherapy (crt)	dipeptidyl peptidase-4 inhibitor
anticancer drug delivery	breast cancer subtypes	child obesity	direct acting antiviral
anti-cancer effects	breast cancer surgery	childhood cancer survivor	childhood cancer antiviral agent
anticancer efficacy	breast cancer susceptibility	childhood cancer survivors	direct-acting antiviral agents
anticancer mechanism	breast cancer therapy	children obesity	direct-acting antivirals
anti-cancer properties	breast cancer xenograft	children with obesity	direct-acting antivirals (daas)
anticancer therapeutic	brexlow thickness	children with type 1 diabetes	disease control rate (dcr)
anticancer therapeutics	bxc-3	chronic hepatitis b patients	disease-free and overall survival
anti-cancer therapy	ca-mrsa	chronic hepatitis c (chc)	disease-specific survival (dss)
anticancer treatments	cancer aggressiveness	chronic hepatitis c infection	disease-specific survival rate
anti-her2	cancer and nutrition	chronic hepatitis c patients	distant metastasis-free survival
anti-hcv	cancer apoptosis	chronic hepatitis c virus (hcv)	downstaging
anti-mrsa	cancer cell apoptosis	chronic hepatitis c virus (hcv) infection	drug use disorder
anti-obesity effect	cancer cell cycle	chronic hepatitis c virus infection	drug-resistant cancer
anti-obesity effects	cancer cell death	chronic hiv	drug-resistant tb
egfr tyrosine kinase inhibitors	ctargin	chronic kidney disease epidemiology collaboration	du-145
egfr-mutant	glargine	chronic kidney disease patient	du145 cell
egfr-mutated	gleason grade	chronic kidney disease patients	du145 cells
egfr-iki	gleason scores	chronic kidney disease stage	ear cancer
egfr-ikis	global initiative for asthma	chronic kidney diseases	eastern cooperative oncology group performance status
end results database	global initiative for chronic obstructive lung disease	chronic thromboembol	ecoc ps
endometrial cancer (ec)	glucagon-like peptide-1 receptor agonist	chronic thromboembolic	effusion lymphoma
endovascular thrombectomy	glucagon-like peptide-1 receptor agonists	chronic thromboembolic pulmonary	egfr inhibitors
end-stage kidney disease (eskd)	glycated haemoglobin (hba1c)	chronic thromboembolic pulmonary hypertension	egfr ik
entecavir	h1n1 pandemic	chronic thromboembolic pulmonary hypertension (cteph)	egfr tki
enzalutamid	h5n1 influenza	circulating tumor dna (ctdna)	egfr tyrosine kinase
enzalutamide	h5n1 virus	circumferential resection margin	egfr tyrosine kinase inhibitor
epidermal growth factor receptor (egfr) mutation	h7n9	hepatitis g virus	hiv knowledge
epidermal growth factor receptor (egfr) mutations	hba 1c	hepatocellular carcinoma (hcc) cells	hiv prevention intervention
epidermal growth factor receptor mutation	hbeag-negative	hepatocellular carcinoma cell line	hiv risk behavior
epidermal growth factor receptor tyrosine kinase inhibitor	hbv dna level	her2 expression	hiv ma level
epidermal growth factor receptor-2	hbv dna levels	her2 overexpression	hiv services
epithelial ovarian cancer (eoc)	hbv genotype	her2 positive	hiv stigma
epithelial?mesenchymal transition (emt)	hbv genotypes	her2 status	hiv viral load
er-positive breast cancer	hbv reactivation	her2+	hiv/hcv
esat-6	hcc cell lines	her2-negative	hiv/sti
escherichia coli (stec)	hcc development	her2-overexpressing	hiv-1 entry
esophageal cancer (ec)	hcc diagnosis	her2-positive breast cancer	hiv-1 integrase
esophageal cancer cell	hcc progression	hereditary breast	hiv-1 subtype
esophageal cancer patients	hcc recurrence	hereditary breast and ovarian cancer	hiv-1 subtypes
european organisation for research and treatment of cancer	hcc risk	hereditary breast cancer	hiv-1 vaccine
european organization for research and treatment of cancer	hcc treatment	hev infection	hiv-1 viral load
european prospective investigation into cancer	hcv coinfection	hev ma	hiv-1-infected patients
european prospective investigation into cancer and nutrition	hcv genotype 1	high hiv prevalence	hiv-associated neurocognitive disorder
european society for medical oncology	hcv patients	high-fat diet-induced obesity	hiv-exposed
exon 19 deletion	hcv replication	high-grade serous	hiv-infected adults
exposure to pm2.5	hcv therapy	highly pathogenic avian influenza	hiv-positive men
extrathyroidal extension	hcv treatment	highly pathogenic avian influenza (hpai)	hiv-related stigma
first-line setting	head and neck cancer (hnc)	highly pathogenic avian influenza virus	hiv-ma
five-year overall survival	head and neck squamous cell carcinomas	high-risk neuroblastoma	hiv-uninfected
flc3-iti	head-and-neck cancer	high-risk prostate cancer	hmih
folfox	health services access	hiv acquisition	hmh1
folfox	health services accessibility	hiv antiretroviral therapy	hmscc cell lines

